Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).
Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract LBA9503).
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).
Thomas A. Jandl, MD, PhD, of Stony Brook University Hospital, discusses data from part 1B of the OLYMPIA-3 trial, which showed that among patients with diffuse large B-cell lymphoma (DLBCL), the safety profile of the first-line combination of odronextamab and CHOP chemotherapy was generally manageable and preliminary efficacy was encouraging, with no meaningful differences between regimens. Additionally, combination with odronextamab did not impact the delivery of CHOP (Abstract 7009).
Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert commentary on the overall survival results from the phase III HARMONi-6 trial presented in this year’s Plenary Session. The study compared ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in previously untreated patients with advanced squamous non–small cell lung cancer (NSCLC) (Abstract LBA4).
